---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-027534"
form_type: "8-K"
ticker: "CODX"
cik: "0001692415"
company_name: "Co-Diagnostics, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T18:15:25.950333+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Revenue collapse to $0.2M, Q2 net loss $8.9M vs $2.7M a year ago

## Summary
- Revenue $0.2M vs $5.0M in prior-year quarter as COVID test demand declined.
- Operating loss of $12.0M increased from $4.1M on pre-commercialization investments in Co-Dx PCR Home platform.
- Net loss $8.9M ($0.31 per share loss) compared to $2.7M loss ($0.08 per share) a year ago.
- Cash and securities $69.1M; repurchased 0.4M shares at avg $1.51 for ~$0.6M.
- Received $1.2M NIH RADx grant and over $2.3M from Gates Foundation for TB/HPV test development.

## SEC filing metadata
- accession: 0001493152-23-027534
- form_type: 8-K
- ticker: CODX
- cik: 0001692415
- company_name: Co-Diagnostics, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1692415/000149315223027534/0001493152-23-027534-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1692415/000149315223027534/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-027534
- JSON: https://secwatch.observer/filing/0001493152-23-027534.json
- Plain text: https://secwatch.observer/filing/0001493152-23-027534.txt

## Key facts
- Earnings Releases
  Co-Diagnostics, Inc. reported second quarter 2023 results: revenue $0.2 million, net income Net loss of $8.9 million, EPS EPS loss of $0.31 per fully diluted share.
  - Period: second quarter 2023
  - Revenue: $0.2 million
  - Net income: Net loss of $8.9 million
  - EPS: EPS loss of $0.31 per fully diluted share
  - Result: reported results
  source text: the development of molecular diagnostic tests, announced today financial results for the quarter ended June 30, 2023. Second Quarter 2023 Financial Results: ● Revenue of $0.2 million, down from $5.0 million during the prior year primarily due to the anticipated decline in global demand for the Logix Smart® COVID-19 tests ● Operating expenses of $11.7
  evidence_url: https://www.sec.gov/Archives/edgar/data/1692415/000149315223027534/0001493152-23-027534-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.